Bradley Pharmaceuticals Inc announced a strategic alliance with Cato Research, an independent full-service research organization. Cato Research specializes in working with pharmaceutical companies to efficiently navigate the regulatory approval process and bring new therapies to market. Bradley will be consulting with Cato on submission to the FDA for new and current products (NDA/ANDA) as well as general development projects. Under terms of the relationship, Bradley Pharmaceuticals and Cato Research will work together to bring novel therapies to fill unmet needs in dermatology, gastroenterology, respiratory and other therapeutic arenas.
The strategic alliance between Bradley Pharmaceuticals and Cato Research will provide enhanced benefits for both companies. Bradley's Management Team continues to implement its strategic growth strategy, which includes acquiring new products, extending the product life cycle of existing products, and introducing new uses for therapies in specific markets, to further expand their key business in Doak Dermatologics and Kenwood Therapeutics. Cato Research has an established and proven track record of success in supporting and providing the evaluation required to bring new therapies, and new uses for existing therapies, to market.
Bradley Pharmaceuticals CEO and President, Daniel Glassman, stated, "The start of this strategic partnership with Cato Research exemplifies Bradley's goal to bring treatments to people who need them. By working with Cato Research, Bradley Pharmaceuticals can streamline the process necessary for faster and more efficient FDA approvals of new therapies."
Cato Research President, Allen Cato, stated, "We look forward to working with Bradley Pharmaceuticals to design product development strategies to meet their business and product enhancement objectives."